These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1462424)

  • 21. [Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy].
    Agabiti-Rosei E
    Drugs; 2003; 63 Spec No 1():19-29. PubMed ID: 12708883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Regression of left ventricular hypertrophy in hypertensive heart disease].
    Hennersdorf MG; Schannwell CM; Schwartzkopff B; Strauer BE
    Herz; 2003 Dec; 28(8):764-78. PubMed ID: 14689112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation of renin-angiotensin system activity to left ventricular hypertrophy and function in experimental and human hypertension.
    Devereux RB; Pickering TG; Cody RJ; Laragh JH
    J Clin Hypertens; 1987 Mar; 3(1):87-103. PubMed ID: 3033158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cardioprotective effects of anti-hypertensive medications].
    Asmar RG
    Curr Med Res Opin; 2005; 21 Suppl 5():S17-21. PubMed ID: 16197648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance vessel structure: effects of treatment.
    Mulvany MJ
    J Cardiovasc Pharmacol; 1991; 17 Suppl 2():S58-63. PubMed ID: 1715487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Major new developments affecting treatment and prognosis in hypertension.
    Gubner RS
    Trans Assoc Life Insur Med Dir Am; 1990; 73():97-114. PubMed ID: 2353405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
    Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin converting enzyme (ACE) inhibitors in experimental hypertension: influence on heart and arteries.
    Levy BI; Salzmann JL; Devissaguet M; Safar ME; Michel JB
    Basic Res Cardiol; 1991; 86 Suppl 1():43-53. PubMed ID: 1827984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cerebrovascular sequelae of hypertension].
    Schrader J; Lüders S; Diener HC
    Herz; 2003 Dec; 28(8):707-16. PubMed ID: 14689105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Left ventricular remodeling and hypertension. Course with antihypertensive therapy].
    Ollivier JP
    Arch Mal Coeur Vaiss; 1991 Dec; 84 Spec No 4():73-7. PubMed ID: 1838922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac hypertrophy and arterial compliance following drug treatment in hypertension.
    Asmar RG; Pannier BM; London GM; Safar ME
    J Cardiovasc Pharmacol; 1991; 18 Suppl 7():S37-9. PubMed ID: 1725199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rational hypertension treatment].
    Canova CR
    Schweiz Med Wochenschr; 1996 Aug; 126(33):1394-9. PubMed ID: 8830397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Regression of left ventricular hypertrophy in hypertensive patients].
    Bosa Ojeda F; García González M; Domínguez Rodríguez A; Barragán Acea A; Miralles Ibarra JM; Lacalzada Almeida J; de Armas Trujillo D
    Rev Esp Cardiol; 1997; 50 Suppl 4():74-6. PubMed ID: 9411592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antihypertensive drug therapy and regression of left ventricular hypertrophy: a review with a focus on diuretics.
    Moser M; Setaro JF
    Eur Heart J; 1991 Sep; 12(9):1034-9. PubMed ID: 1834464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of structural changes in hypertensive arteries--a major prospect for the future.
    Rosendorff C
    S Afr Med J; 1991 Sep; Suppl():4-6. PubMed ID: 1925814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.